Articles
November 11, 2022 – Daiichi Sankyo Wins EU Backing for Enhertu in Gastric Cancer
An expert panel of the European Medicines Agency (EMA) has recommended issuing marketing authorization for Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) to include gastric cancer as an indication for Enhertu, an antibody-drug conjugate the company develops with AstraZeneca (NASDAQ:AZN). Read more>
Read MoreNovember 8, 2022 – The Role of H. pylori in Gastric Cancer
Newswise — Helicobacter pylori (H. pylori) infection is a major cause of gastric cancer, and researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have several projects underway to better understand the association and develop much-needed prevention and treatment. Read more >
Read MoreOctober 30, 2022 – Talking About Grief with Anderson Cooper
When the CNN anchor Anderson Cooper was ten, he lost his father, Wyatt, to heart disease; when he was twenty-one, his older brother Carter died by suicide. In 2019, his mother, the artist, and clothing designer Gloria Vanderbilt, passed away at ninety-five, of stomach cancer. (Vanderbilt had watched, desperate and helpless, as Carter leapt from…
Read MoreOctober 29, 2022 – Low Sodium Diet: What You Need to Know about This Popular Diet?
Sodium is an important mineral that helps your body perform many vital functions. It can be found in foods like eggs and vegetables, and it is also a big part of table salt (sodium chloride). Even though sodium is beneficial to health, it is not always recommended. For example, people with heart failure, high blood…
Read MoreOctober 25, 2022 – ICR Study Raises Possibility of Predicting Drug Resistance in Advance
A new study led by scientists at the Institute of Cancer Research, London (ICR) and The Royal Marsden NHS Foundation Trust has shown how stomach cancers can evade the effects of a new class of drugs, raising the possibility of being able to predict drug resistance in advance. The researchers found that stomach cancers could…
Read MoreSeptember 22, 2022 – A Phase II Study of Domvanalimab and Zimberelimab Immunotherapy with or without FOLFOX Chemotherapy in People with Esophageal, Gastroesophageal Junction, or Stomach Cancer
The purpose of this study is to assess the safety and effectiveness of the investigational drugs domvanalimab and zimberelimab given together with or without FOLFOX chemotherapy in people with inoperable or metastatic upper digestive cancers. Both domvanalimab and zimberelimab take the brakes off the immune response by blocking certain proteins, enabling the immune system to…
Read MoreSeptember 19, 2022 – Minimally Invasive Robotic and Laparoscopic Gastrectomy: A new ray of hope for gastric cancer
The stomach is a muscular J-shaped sac-like structure, mainly acts as reservoir for the food, located in the upper and left part of the abdomen and a crucial part of the Digestive organ of gastrointestinal system. It produces enzymes (Substances that create chemical reactions) and acids (digestive juices). This mix of enzymes and digestive juices…
Read MoreSeptember 18, 2022 – First signs of esophageal cancer: You can recognize it early on with these warning signs
Die esophagus belongs to gastrointestinal tract and transports food from the throat to the stomach. Cancer of the esophagus is comparatively rare in Germany: men are four to five times more likely than women. The median age at diagnosis is 67 for men and 71 for women. The insidious thing about the disease: Symptoms usually…
Read MoreSeptember 9, 2022 – ASCO: Amgen’s Stomach Cancer Drug, Nabbed in Five Prime Buyouts, Extends Patients’ Lives in Phase 2
Amgen battled other biopharma suitors for Five Prime Therapeutics early this year, emerging victorious in March with a $1.9 billion deal to snap up the cancer-focused biotech. Now, the company is painting a fuller picture for bemarituzumab, the crown jewel of the buyout, showing the treatment helped patients with advanced stomach cancer live longer. Read…
Read MoreSeptember 1, 2022 – Grant Supports Research to Study Gastric Cancer Origins
Two Vanderbilt-Ingram Cancer Center researchers have received $5 million in funding from a new initiative by the National Cancer Institute that aims to define how gastric and gastroesophageal junction adenocarcinomas form and evolve at the cellular level. >>Read More
Read More